Intra-Cellular Therapies Inc (BSP:I2TC34)
R$ 84.24 0 (0%) Market Cap: 8.93 Bil Enterprise Value: 2.80 Bil PE Ratio: 0 PB Ratio: 7.86 GF Score: 31/100

Q1 2023 Intra-Cellular Therapies Inc Earnings Call Transcript

May 04, 2023 / 12:30PM GMT
Operator

Good morning, and welcome to Intra-Cellular Therapies first quarter financial results conference call. (Operator Instructions) Please be advised that today's conference call is being recorded.

I would now like to turn the conference over to Dr. Juan Sanchez, Vice President, Corporate Communications and Investor Relations. Please go ahead.

Juan Fernando Sanchez
Intra-Cellular Therapies, Inc. - VP of Corporate Communications & IR

Good morning, and thank you all for being here today. Joining me on the call today are Dr. Sharon Mates, Chairman and Chief Executive Officer; Mark Neumann, Chief Commercial Officer; Dr. Suresh Durgam, Chief Medical Officer; and Larry Hineline, Chief Financial Officer.

As a reminder, during today's call, we will be making certain forward-looking statements. These forward-looking statements are based on current information, assumptions and expectations. Those are subject to change and involve a number of risks and uncertainties that may cause actual results to differ materially from those contained in the forward

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot